Polypeptide variants with altered effector function
AssigneeGenentech, Inc.
InventorLeonard Presta
Life of this patent
Estimating the term…
Abstract
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Claims19
An antibody comprising a variant human IgG1 Fc region, which antibody comprises an amino acid substitution at any one or more of amino acid positions 265 or 269 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An antibody comprising a variant human IgG1 Fc region, which antibody comprises an amino acid substitution at two or more of amino acid positions 265, 269, 270, 297 or 327 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An antibody comprising a variant human IgG1 Fc region, wherein the amino acid residue at any one or more of amino acid positions 265 or 269 of the Fc region is substituted with Ala, and wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An antibody that binds to vascular endothelial growth factor (VEGF) comprising a variant human IgG1 Fc region, which antibody comprises an amino acid substitution at any one or more of amino acid positions 265 or 269 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An immunoadhesin comprising a variant human IgG1 Fc, which immunoadhesin comprises an amino acid substitution at any one or more of amino acid positions 265 or 269 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An immunoadhesin comprising a variant human IgG1 Fc region, which immunoadhesin comprises an amino acid substitution at two or more of amino acid positions 265, 269, 270, 297 or 327 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
An immunoadhesin comprising a variant human IgG1 Fc region, wherein the amino acid residue at any one or more of amino acid positions 265 or 269 of the Fc region is substituted with Ala, and wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
Dependencies are inferred from the claim text.